NASDAQ:INSY - Insys Therapeutics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$8.24 +0.37 (+4.70 %)
(As of 06/20/2018 04:00 PM ET)
Previous Close$7.87
Today's Range$7.90 - $8.35
52-Week Range$4.10 - $14.00
Volume944,377 shs
Average Volume1.06 million shs
Market Capitalization$572.76 million
P/E Ratio-16.82
Dividend YieldN/A
Beta1.09
Insys Therapeutics logoInsys Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes supportive care products. The company markets SUBSYS, a sublingual fentanyl spray for breakthrough cancer pain in opioid-tolerant adult patients; and SYNDROS, an orally administered liquid formulation of dronabinol for the treatment of chemotherapy-induced nausea and vomiting, and anorexia associated with weight loss in patients with AIDS. It is also developing Cannabidiol Oral Solution, which has completed pediatric study for the treatment of pediatric epilepsy; has completed Phase II study to treat west syndrome; and is in Phase II study for the treatment of childhood absence epilepsy, as well as Buprenorphine Sublingual Spray that has completed Phase III study to treat acute pain. In addition, the company is developing Cannabidiol Oral Solution for the treatment of prader willi; Buprenorphine/Naloxone Sublingual Spray to treat opioid dependence; and Naloxone Nasal Spray for the treatment of opioid antagonist. Insys Therapeutics, Inc. is headquartered in Chandler, Arizona.

Receive INSY News and Ratings via Email

Sign-up to receive the latest news and ratings for INSY and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:INSY
CUSIPN/A
Phone480-500-3127

Debt

Debt-to-Equity RatioN/A
Current Ratio0.84
Quick Ratio0.76

Price-To-Earnings

Trailing P/E Ratio-16.82
Forward P/E Ratio-9.05
P/E GrowthN/A

Sales & Book Value

Annual Sales$140.69 million
Price / Sales4.32
Cash FlowN/A
Price / CashN/A
Book Value$0.86 per share
Price / Book9.58

Profitability

EPS (Most Recent Fiscal Year)($0.49)
Net Income$-228,010,000.00
Net Margins-188.01%
Return on Equity-43.27%
Return on Assets-17.51%

Miscellaneous

Employees343
Outstanding Shares73,810,000

Insys Therapeutics (NASDAQ:INSY) Frequently Asked Questions

What is Insys Therapeutics' stock symbol?

Insys Therapeutics trades on the NASDAQ under the ticker symbol "INSY."

When did Insys Therapeutics' stock split? How did Insys Therapeutics' stock split work?

Shares of Insys Therapeutics split before market open on Monday, March 31st 2014. The 3-2 split was announced on Tuesday, March 4th 2014. The newly created shares were issued to shareholders after the closing bell on Friday, March 28th 2014. An investor that had 100 shares of Insys Therapeutics stock prior to the split would have 150 shares after the split.

How were Insys Therapeutics' earnings last quarter?

Insys Therapeutics Inc (NASDAQ:INSY) posted its earnings results on Tuesday, May, 8th. The specialty pharmaceutical company reported ($0.19) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.18) by $0.01. The specialty pharmaceutical company had revenue of $23.90 million for the quarter, compared to analyst estimates of $25.82 million. Insys Therapeutics had a negative net margin of 188.01% and a negative return on equity of 43.27%. The company's revenue was down 33.4% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.09) EPS. View Insys Therapeutics' Earnings History.

When is Insys Therapeutics' next earnings date?

Insys Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, August, 1st 2018. View Earnings Estimates for Insys Therapeutics.

What price target have analysts set for INSY?

5 brokerages have issued 12 month price objectives for Insys Therapeutics' stock. Their forecasts range from $8.00 to $11.00. On average, they anticipate Insys Therapeutics' share price to reach $9.6667 in the next twelve months. View Analyst Ratings for Insys Therapeutics.

Who are some of Insys Therapeutics' key competitors?

Who are Insys Therapeutics' key executives?

Insys Therapeutics' management team includes the folowing people:
  • Mr. Steven J. Meyer, Exec. Chairman (Age 61)
  • Mr. Saeed Motahari, CEO, Pres & Director (Age 52)
  • Mr. Andrew G. Long, Chief Financial Officer
  • Mr. Franc Del Fosse, Gen. Counsel & Corp. Sec. (Age 46)
  • Mr. B. Sanga Emmanuel, VP & Chief Compliance Officer

Has Insys Therapeutics been receiving favorable news coverage?

Media stories about INSY stock have trended somewhat positive recently, Accern Sentiment Analysis reports. Accern identifies positive and negative media coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Insys Therapeutics earned a daily sentiment score of 0.05 on Accern's scale. They also gave news headlines about the specialty pharmaceutical company an impact score of 45.08 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the next few days.

Who are Insys Therapeutics' major shareholders?

Insys Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include BlackRock Inc. (3.31%), ETF Managers Group LLC (0.88%), DekaBank Deutsche Girozentrale (0.04%) and JPMorgan Chase & Co. (0.03%). Company insiders that own Insys Therapeutics stock include Brian Tambi, Daniel Brennan, John N Kapoor Trust Dated Sept, Patrick Fourteau, Rohit Vishnoi, Saeed Motahari, Steven J Meyer and Theodore H Stanley. View Institutional Ownership Trends for Insys Therapeutics.

Which institutional investors are selling Insys Therapeutics stock?

INSY stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc. and DekaBank Deutsche Girozentrale. View Insider Buying and Selling for Insys Therapeutics.

Which institutional investors are buying Insys Therapeutics stock?

INSY stock was acquired by a variety of institutional investors in the last quarter, including ETF Managers Group LLC and JPMorgan Chase & Co.. Company insiders that have bought Insys Therapeutics stock in the last two years include John N Kapoor Trust Dated Sept, Rohit Vishnoi, Saeed Motahari and Steven J Meyer. View Insider Buying and Selling for Insys Therapeutics.

How do I buy shares of Insys Therapeutics?

Shares of INSY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Insys Therapeutics' stock price today?

One share of INSY stock can currently be purchased for approximately $8.24.

How big of a company is Insys Therapeutics?

Insys Therapeutics has a market capitalization of $572.76 million and generates $140.69 million in revenue each year. The specialty pharmaceutical company earns $-228,010,000.00 in net income (profit) each year or ($0.49) on an earnings per share basis. Insys Therapeutics employs 343 workers across the globe.

How can I contact Insys Therapeutics?

Insys Therapeutics' mailing address is 1333 S. Spectrum Blvd Suite 100, Chandler AZ, 85286. The specialty pharmaceutical company can be reached via phone at 480-500-3127 or via email at [email protected]


MarketBeat Community Rating for Insys Therapeutics (INSY)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  326 (Vote Outperform)
Underperform Votes:  241 (Vote Underperform)
Total Votes:  567
MarketBeat's community ratings are surveys of what our community members think about Insys Therapeutics and other stocks. Vote "Outperform" if you believe INSY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe INSY will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.